Can a new antibody calm inflammation? a First-in-Human test begins
NCT ID NCT04220073
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether a single dose of an experimental antibody called JS005 is safe and well-tolerated in healthy volunteers. The antibody targets IL-17A, a protein that drives inflammation, and could one day help treat inflammatory diseases. The study will also look at how the body processes the drug and whether it triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JS005, an experimental humanized monoclonal antibody that targets IL-17A, a protein involved in inflammation
- What this could lead to
- If successful, this could pave the way for developing a treatment for inflammatory conditions like psoriasis or arthritis.
- What could go wrong
- This is an early-phase trial with a small number of healthy volunteers, so results may not predict effects in patients. There is also a risk of unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOLERABILITY, SAFETY, IMMUNOGENICITY AND PHARMACOKINETIC OF JS005 are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Luhe Hospital Capital Medical University
Beijing, Beijing Municipality, 101149, China